In non-DM patients, P2Y12 inhibitor monotherapy had a similar risk of MACCE compared to DAPT (OR: 0.99, 95% CI: 0.82–1.19, p = 0.89, I2 = 27%, PHeterogeneity = 0.25). This evidence concerns the gene P2RY12 and diabetes mellitus.